Clinically Tested


Sinomarin® - Clinically Tested

Efficacy on nasal obstruction of various etiologies

Open study investigating the efficacy and tolerance of Sinomarin® on patients with various nasal and/or sinus disorders, resulting in permanent or intermittent nasal
obstruction1.

80 adult patients receiving Sinomarin® monotherapy for 2 weeks, 3 times per day, 2 applications per nostril.

Significant Improvement in nasal obstruction 77,4% of cases
Significant Improvement on general symptomatology 81% of cases
Good or excellent tolerance 95% of cases

Effective adjunct treatment for Rhinitis

An investigational, prospective, longitudinal, comparative, multicenter, open-label study on the efficacy and tolerance of Sinomarin® for the treatment of rhinitis2.

333 patients over 12 years of age. 20 day protocol with 3 visits to physician (Visit #1= Baseline – treatment initiation; Visit #2 = day 10; Visit #3 = day 20- end of treatment); 2 investigation groups: 1) Sinomarin® plus treatment, 2) treatment without Sinomarin® (control group). Medicinal treatments were dependent on condition. Results based on Analog Scales (1-12).

Patients using Sinomarin® as an adjunct treatment demonstrated statistically significant efficacy versus control group (prescribed treatment alone) from the second visit onwards, in all parameters evaluated i.e. nasal obstruction (Fig. 1), level of rhinorrhea (Fig. 2), nasal comfort, tolerance, patient & investigator opinion.

Effective on the nasal mucosa following surgery

A prospective randomized study investigating the effect of different irrigation solutions (incl. sea water at 2.3% NaCl) on mucocilliary activity & nasal patency, on patients following nasal surgery (septoplasty)22.

45 septoplasty patients; 3 randomly divided investigation groups receiving: 1) 2.3% buffered hypertonic seawater, 2) buffered isotonic saline solution, 3) non-buffered isotonic saline; post-operative administration of irrigation solutions for 20 days, 6 applications per nostril per day.

Nasal Airway Patency

On 20th postoperative day Difference from 5th day
(mean ± SD) (cm2)
Difference from 5th day
(mean ± SD) (%)
NAP (2.3% buffered hypertonic saline) 0.37 ± 0.19 62.6 ± 43.4
NAP (2.3% buffered isotonic saline) 0.15 ± 0.20 26.3 ± 38.3

Treatment with 2.3% buffered hypertonic saline solutions improved nasal patency between the 5th and 20th post-operative days following septoplasty. This improvement was superior to the effect observed with 0.9% buffered isotonic solutions in a statistically significant manner (p = 0.042).

Buffered hypertonic solutions used following endonasal surgery decrease inflammation of the nasal mucosa resulting in a significant decongestive effect. They present superior efficacy to isotonic solutions.

1. Freche C et al., “Usefulness of hypertonic sea water (Sinomarin®) in rhinology”, Revue Officielle de la Société Française de ORL, 50(4), 1998.
2. González G et al., “A clinical study conducted in 2007 with Mexican patients: an investigational, prospective, longitudinal, comparative, multicentre, open-label study on the efficacy and tolerability of Sinomarin Spray for the treatment of rhinitis”, Journal of the Federation of Otalaryngological and Societies of the Mexican Republic (FESORMEX), 2008.
22. Süslü N. et al., ‘Effects of buffered 2.3%, buffered 0.9%, and non-buffered 0.9% irrigation solutions on nasal mucosa after septoplasty”, Eur Arch Otorhinolaryngol (2009) 266:685–689.